bf93be3e-d4f1-4efb-9841-ca8ad81b237e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.440
- P53_PATHWAY+0.370
- PROTEIN_SECRETION+0.350
- MYC_TARGETS_V1+0.330
- MTORC1_SIGNALING+0.300
- GLYCOLYSIS+0.290
- ESTROGEN_RESPONSE_LATE+0.280
- FATTY_ACID_METABOLISM+0.280
- PEROXISOME+0.260
- XENOBIOTIC_METABOLISM+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- INTERFERON_GAMMA_RESPONSE-0.300
- MITOTIC_SPINDLE-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.230
- MYOGENESIS-0.220
- G2M_CHECKPOINT-0.210
- ANGIOGENESIS-0.180
- APICAL_JUNCTION-0.180
- HEDGEHOG_SIGNALING-0.170
- UV_RESPONSE_DN-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-IQ-7632-01A-11R-2081-07 | — | — | 0.825 |
| 2 | SRR8943024 | — | — | 0.812 |
| 3 | AUR-AD9I-TTM3-A-1-1-R-A542-39 | — | C | 0.788 |
| 4 | TCGA-E2-A1LB-01A-11R-A144-07 | — | F | 0.781 |
| 5 | e94b6daf-3aed-4496-b64b-1b1a7d8e2011 | — | — | 0.781 |
| 6 | TCGA-B6-A0RO-01A-22R-A084-07 | — | C | 0.779 |
| 7 | da1c4d8d-b07a-4aa1-8360-1c140ca16327 | — | — | 0.774 |
| 8 | 3d6b96fa-5efa-4c8a-9a12-2718304252d4 | — | — | 0.769 |
| 9 | TCGA-CV-7437-01A-21R-2132-07 | — | — | 0.769 |
| 10 | 79a36f11-38bb-42ed-a95a-ae2a9eea0f6a | — | — | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.370 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |